UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (359) 359
life sciences & biomedicine (341) 341
oncology (282) 282
humans (278) 278
female (231) 231
male (224) 224
middle aged (214) 214
aged (194) 194
adult (175) 175
lung neoplasms - drug therapy (123) 123
carcinoma, non-small-cell lung - drug therapy (110) 110
lung neoplasms - pathology (93) 93
aged, 80 and over (91) 91
respiratory system (89) 89
treatment outcome (81) 81
mutation (74) 74
cancer (70) 70
lung cancer (70) 70
lung cancer, non-small cell (70) 70
chemotherapy (68) 68
carcinoma, non-small-cell lung - pathology (62) 62
care and treatment (62) 62
retrospective studies (62) 62
prognosis (61) 61
antineoplastic combined chemotherapy protocols - therapeutic use (60) 60
lung neoplasms - genetics (59) 59
neoplasm staging (58) 58
non-small cell lung cancer (57) 57
disease-free survival (55) 55
antineoplastic agents - therapeutic use (51) 51
carcinoma, non-small-cell lung - genetics (49) 49
lung neoplasms - mortality (46) 46
original (46) 46
protein kinase inhibitors - therapeutic use (46) 46
original article (43) 43
metastasis (39) 39
analysis (38) 38
hematology, oncology and palliative medicine (38) 38
patients (38) 38
survival rate (38) 38
carcinoma, non-small-cell lung - mortality (37) 37
medical colleges (37) 37
receptor, epidermal growth factor - genetics (34) 34
tumors (33) 33
follow-up studies (32) 32
pulmonary and respiratory medicine (32) 32
non-small cell lung carcinoma (30) 30
pemetrexed (30) 30
pulmonary/respiratory (30) 30
research (30) 30
cisplatin - administration & dosage (29) 29
epidermal growth factor (29) 29
medicine & public health (29) 29
survival analysis (28) 28
의약학 (27) 27
abridged index medicus (26) 26
adenocarcinoma - drug therapy (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (26) 26
cancer therapies (26) 26
disease progression (26) 26
nsclc (26) 26
pathology (26) 26
epidermal growth factor receptor (25) 25
gefitinib (25) 25
adenocarcinoma - pathology (24) 24
lung neoplasms - metabolism (24) 24
quinazolines - therapeutic use (24) 24
clinical trials (23) 23
kaplan-meier estimate (23) 23
surgery (23) 23
tyrosine (23) 23
prospective studies (22) 22
young adult (22) 22
patient outcomes (21) 21
pharmacology & pharmacy (21) 21
receptor, epidermal growth factor - antagonists & inhibitors (21) 21
respiratory tract diseases (21) 21
adenocarcinoma (20) 20
antineoplastic agents - adverse effects (20) 20
erbb receptors - genetics (20) 20
general & internal medicine (20) 20
immunotherapy (20) 20
biomarkers (19) 19
non-small-cell lung cancer (19) 19
protein kinase inhibitors - administration & dosage (19) 19
carcinoma, non-small-cell lung - metabolism (18) 18
cisplatin (18) 18
genetic aspects (18) 18
lung cancer, small cell (18) 18
medicine, general & internal (18) 18
radiology, nuclear medicine & medical imaging (18) 18
survival (18) 18
tomography, x-ray computed (18) 18
adenocarcinoma - genetics (17) 17
antimitotic agents (17) 17
antineoplastic agents (17) 17
carcinoma (17) 17
cell biology (17) 17
epidermal growth factor receptors (17) 17
guanine - analogs & derivatives (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Cell survival | Medical treatment | FDA approval | Health care facilities | Survival | Patients | Evidence-based medicine | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2016, Volume 122, Issue 19, pp. 3024 - 3031
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 04/2012, Volume 30, Issue 10, pp. 1122 - 1128
Journal Article
PloS one, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, pp. e64816 - e64816
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 121 - 128
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Scientific reports, ISSN 2045-2322, 06/2019, Volume 9, Issue 1, pp. 8730 - 9
... of Radiomic Features in patients with Advanced Non-small Cell Lung Cancer so Hyeon Bak 1,3, Hyunjin park4,5, Insuk sohn6, Seung Hak Lee7, Myung-Ju Ahn8 & Ho Yun Lee1,2... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biomarkers | Non-small cell lung carcinoma | Entropy | Prediction models | Lung cancer | Index Medicus
Journal Article